TELESTA THERAPEUTICS INC T.TST

35% CRR on Papillary

[beechguy]

I am annoyed that they don't mention the fact the Papillary patients (that are 90% of NMIBC population base) had a complete response of 35%. A third of BCG refractory patients will have an alternative to Cystectomy (bladder removal). If we use Berendt's numbers from the AGM - 80k BC patients in US annually. 80% are NMIBC. Of those 80% will become refractory to BCG within 2 years. 90% of those are Papillary. 15-24 instillations at (the revised) $4000 per instillation. If we use a 25% penetration number (conservative) that leaves us 11,520 Papillary patients. At $60,000 full instillation. (lower end of cited numbers) that is $691,200,000 USD in peak revenue. $864mm CDN. At the meagerest revenue multiple of 2 x revenue (should be 4 x) that is 1.728B valuation. That is $8.64 / share . That is without Canada and the rest of the world. At some point big investors will figure this out. I hope before we get bought out for pennies on the dollar. All of you that are sick of this circuitous route this company has taken over the years (vast majority of it from the previous regime) and selling shares, should consider what you may be leaving on the table. Less than a year from now, if the FDA rules in our favour (at an FDA panel discussion one member said Urocidin /MCNA is a much needed treatment for BC patients and the FDA advised to file with existing dataset without a phase 3B trial), we are likely looking at a $8 - $15 stock. It all starts when we get through the pivotal .42 range. Have a look at EDT chart if you want to see what our chart should look like after the breakout occurs. beech

[BenTan]

Just trying to be realistic here (I'm also invested in this stock), but you can't be the only one who has figured out the math. I'm being cautiously optimistic which is why I'm wondering why there hasnt' been any interest from institutional investors. I had plenty of time over the last month to buy in the $0.34 range. You would think that usually everything good about the

[loveshackdave]

I seem to remember that somone brought this up before and it turned out that the statistical certainty of the 35% number wasn't high enough to go to the FDA with without additional data. Because of this, they have tried not to highlight it so that they appear to give a consistent message to both the FDA and to investors. Can't remember who said this but I think it was on this board.

[DamnYankees]

Shack, while I am not a pom pom waving fan of current management I am fine with them managing the parameters of the FDA submission and being uber conservative on their CR projections. To those that wonder how this "to good to be true" opportunity has flown under the radar you may, and I mean may, only need to look no further than what would be in the immediate interest of their many

[cheetio]

80 cent buyout of a $5.00 - $10.00 property ...Levi & Korsinsky LLP